Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo

Bioalliance Pharma and Topotarget Shareholders Approve Proposed Cross-Border Merger to Create Onxeo

Judith Greciet, +33 1 45 58 76 00Chief Executive OfficerorCaroline Carmagnol - AlizéeRP+33 6 64 18 99 59orBo Jesper Hansen, +45 26 12 83 84Chairman of the Board of DirectorsorAnders Vadsholt, +45 28 98 90 55Chief Executive OfficerorMichael Steen-Knudsen, +45 25 17 18 15Impact Communications

Regulatory News:

BioAlliance Pharma SA (Paris:BIO) (Euronext Paris - BIO), an innovative company specializing in the development of drugs for orphan oncology diseases, and Topotarget A/S (NASDAQ OMX - TOPO), a Danish based biopharmaceutical company focusing on late-stage clinical development for orphan oncology, today announce that the shareholders of both companies have approved all resolutions with more than 99% voting in favor of the proposed cross-border merger between BioAlliance Pharma SA and Topotarget A/S on 27 June 2014 and 30 June 2014.

The combined entity aims to become a leading orphan oncology company and will be renamed Onxeo upon completion of the merger.

With a portfolio of advanced programs targeting severe orphan oncology diseases for which there is an unmet medical need, Onxeo will offer increased market attractiveness, notably towards specialized international investors, using its scale and significant footprint as a biotechnology leader with a growing portfolio of high value-added products.

The shareholders also approved the appointment of Orfacare Consulting GmbH, represented by Mr. Bo Jesper Hansen, and of Mr. Per Samuelsson, of Healthcap, as board members of Onxeo, effective as of the completion of the merger. As previously announced, Judith Greciet will be the CEO of Onxeo and Patrick Langlois the Chairman of the Board of Directors.

Following approval of the merger by the companies’ shareholders, the completion of the merger is now subject to registration by the relevant French and Danish authorities, which is expected to occur in the course of July 2014.

The expected last day of trading of TopoTarget on NASDAQ OMX Copenhagen and expected first day of trading of BioAlliance (renamed Onxeo) on NASDAQ OMX Copenhagen will be announced in due course.

Dedicated to cancer treatments with a focus on resistance targeting and orphan products, BioAlliance Pharma conceives and develops innovative products for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma’s ambition is to become a leading player in these fields by coupling innovation to patient needs. The company’s teams have the key competencies required to identify, develop and register drugs in Europe and the USA.

BioAlliance Pharma has developed an advanced product portfolio:

Livatag (Doxorubicin Transdrug™) (primary liver cancer): Phase III on goingValidive (Clonidine Lauriad) (mucositis): Phase II on goingAMEP/Synfoldin (invasive melanoma): Clinical and Preclinical Phase

For more information, visit the BioAlliance Pharma website at

Topotarget (NASDAQ OMX: TOPO) is a Danish-based biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy.

For more information, please refer to

Suggested Articles

Cancer biotech Zentalis Pharmaceuticals priced its IPO at $165 million, eclipsing the $100 million goal it laid out in early March.

The agreement gives Innovax access to a GSK adjuvant to enhance the immune response triggered by its recombinant protein-based vaccine.

Johnson & Johnson is paying Fate Therapeutics $50 million upfront to collaborate on up to four CAR NK and CAR-T cell therapies.